The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that summarize the presentations and discussions that occurred at two symposia in 2011 sponsored by the Frontotemporal Degeneration Treatment Study Group, a collaborative group of academic and industry researchers that is devoted to developing treatments for FTD. This article discusses the current status of FTD clinical research that is relevant to the conduct of clinical trials, and why FTD research may be an attractive pathway for developing therapies for neurodegenerative disorders. The clinical and molecular features of FTD, including rapid disease progression and relatively pure molecular pathology, suggest that there are advantages to developing drugs for FTD as compared with other dementias. FTD qualifies as orphan indication, providing additional advantages for drug development. Two recent sets of consensus diagnostic criteria will facilitate the identification of patients with FTD, and a variety of neuropsychological, functional, and behavioral scales have been shown to be sensitive to disease progression. Moreover, quantitative neuroimaging measurements demonstrate progressive brain atrophy in FTD at rates that may surpass Alzheimer's disease. Finally, the similarities between FTD and other neurodegenerative diseases with drug development efforts already underway suggest that FTD researchers will be able to draw on this experience to create a road map for FTD drug development. We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationLitvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Mioshi, E., Dawson, K., Mitchell, J., Arnold, R., & Hodges, J. R. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1610 · Cited by 2,016
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia
Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000) · Neurology · doi:10.1212/01.wnl.0000434309.85312.19 · Cited by 1,029 · cited 1×
“[43] Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR.”
BackgroundTang, W., Lu, Y., Tian, Q.-Y., Zhang, Y., Guo, F.-J., Liu, G.-Y., Syed, N. M., Lai, Y., Lin, E. A., Kong, L., et al. (2011) · Science · doi:10.1126/science.1199214 · Cited by 761
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · cited 3×
“The Dominantly Inherited Alzheimer's Network (DIAN) is a NIA-sponsored, international effort to study individuals with autosomal dominantly inherited AD (ADAD) 59 Although less of a clearinghouse than a collaborative research effort focused on understanding and treating inherited forms of AD, DIAN has developed resear…”
BackgroundInfluentialSelf-citationFrontal behavioral inventory: diagnostic criteria for frontal lobe dementi
Kertesz, A., Davidson, W., & Fox, H. (1997) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100021053 · Cited by 571 · cited 1×
“[48] Kertesz A, Davidson W, Fox H.”
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. (2008) · Brain · doi:10.1093/brain/awn234 · Cited by 442
Self-citationAdvances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
Research works printed but not linked: 47
- Hu B, 2010, Off‐label medication use in frontotemporal dementia, Am J Alzheimers Dis Other Demen, 25, 128, 10.1177/1533317509356692 · DOI · Paper page
- 10.1007/s00401-008-0460-5 · DOI · Paper page
- 10.1038/clpt.2010.193 · doi:10.1038/clpt.2010.193
- 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
- 10.1001/archneurol.2010.343 · DOI · Paper page
- 10.1212/01.wnl.0000171343.43314.6e · DOI · Paper page
- 10.1212/01.wnl.0000173837.82820.9f · DOI · Paper page
- 10.1093/brain/awn291 · DOI · Paper page
- 10.1093/brain/awm021 · DOI · Paper page
- 10.1016/j.parkreldis.2011.10.013 · DOI · Paper page
- 10.1016/S1474-4422(08)70194-7 · DOI · Paper page
- 10.1093/brain/awn352 · DOI · Paper page
- 10.1523/JNEUROSCI.5757-10.2011 · DOI · Paper page
- 10.1074/jbc.M110.193433 · DOI · Paper page
- 10.1212/WNL.58.11.1615 · DOI · Paper page
- 10.1212/WNL.0b013e3181f5d4c4 · DOI · Paper page
- 10.1212/01.WNL.0000106827.39764.7E · DOI · Paper page
- 10.1212/01.wnl.0000334277.16896.fa · DOI · Paper page
- 10.1212/WNL.38.7.1031 · DOI · Paper page
- 10.1093/brain/124.7.1438 · DOI · Paper page
- 10.1159/000077171 · DOI · Paper page
- 10.1159/000067021 · DOI · Paper page
- 10.1007/s00213-003-1686-5 · DOI · Paper page
- 10.1097/WAD.0b013e318197852f · DOI · Paper page
- 10.3233/JAD-2010-101632 · DOI · Paper page
- 10.1093/brain/awr171 · DOI · Paper page
- 10.1212/WNL.57.3.467 · DOI · Paper page
- 10.1002/mds.22023 · DOI · Paper page
- 10.1016/S1474-4422(11)70024-2 · DOI
- 10.1016/j.neuron.2011.09.011 · DOI · Paper page
- 10.1212/01.wnl.0000313366.76973.8a · DOI · Paper page
- 10.1159/000327169 · DOI
- 10.1212/WNL.0b013e318258f785 · DOI
- 10.1016/j.jalz.2007.04.374 · DOI · Paper page
- 10.1097/WAD.0b013e318182d293 · DOI · Paper page
- 10.1136/jnnp.2007.122028 · DOI · Paper page
- 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- CrawfordS WhitnallL RobertsonJ EvansJJ.A systematic review of the accuracy and clinical utility of the Addenbrooke's Cognitive Examination and the Addenbrooke's Cognitive Examination‐Revised in the diagnosis of dementia.Int J Geriatr Psychiatry(in press).
- 10.1371/journal.pone.0022293 · DOI
- 10.1001/archneurol.2009.92 · DOI · Paper page
- 10.1093/brain/awm032 · DOI · Paper page
- 10.1212/WNL.0b013e318200d78d · DOI · Paper page
- 10.1212/WNL.0b013e318227047f · DOI · Paper page
- 10.1001/jama.2009.1863 · DOI
- Rai A, 2008, Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery, Yale J Health Policy Law Ethics, 8, 53
- 10.1038/clpt.2009.165 · DOI · Paper page
- 10.1001/jama.2011.1837 · DOI
Cited by
Olney, N. T., Spina, S., & Miller, B. L. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.008 · Cited by 419
Self-citationBoxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294
Self-citationFrontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine
Irwin, D. J., Cairns, N. J., Grossman, M., McMillan, C. T., Lee, E. B., Van Deerlin, V. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1380-1 · Cited by 264
Self-citationScherling, C. S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J. H., Rabinovici, G., Ahlijanian, M., Miller, B. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24052 · Cited by 249
“We investigated the clinical correlates of elevated CSF NfL levels in FTD. Methods: CSF NfL, amyloid-b1–42 (Ab42), tau, and phosphorylated tau concentrations were compared in 47 normal controls (NC), 8 asymptomatic gene carriers (NC2) of FTD-causing mutations, and 79 FTD (45 behavioral variant frontotemporal dementia…”
InfluentialSelf-citationBoxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C.-K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70320-4 · Cited by 228
Self-citation
Metadata
- Authors
- Boxer, A. L., Gold, M., Huey, E., Hu, W. T., Rosen, H., Kramer, J., Gao, F., Burton, E. A., Chow, T., Kao, A., Leavitt, B. R., Lamb, B., Grether, M., Knopman, D., Cairns, N. J., Mackenzie, I. R., Mitic, L., Roberson, E. D., Van Kammen, D., Cantillon, M., Zahs, K., Jackson, G., Salloway, S., Morris, J., Tong, G., Feldman, H., Fillit, H., Dickinson, S., Khachaturian, Z. S., Sutherland, M., Abushakra, S., Lewcock, J., Farese, R., Kenet, R. O., LaFerla, F., Perrin, S., Whitaker, S., Honig, L., Mesulam, M. M., Boeve, B., Grossman, M., Miller, B. L., & Cummings, J. L.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2012-10-12
- Volume
- 9
- Issue
- 2
- Pages
- 189-198
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2043778544
- Cited by
- 54
- References
- 20
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier). https://app.cochat.ai/papers/10.1016/j.jalz.2012.03.003
- The paper
- Boxer, A. L., Gold, M., Huey, E., Hu, W. T., Rosen, H., Kramer, J., Gao, F., Burton, E. A., Chow, T., Kao, A., Leavitt, B. R., Lamb, B., Grether, M., Knopman, D., Cairns, N. J., Mackenzie, I. R., Mitic, L., Roberson, E. D., Van Kammen, D., . . . Cummings, J. L. (2013). The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier). Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2012.03.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.